CORT ▼ -0.1% - Corcept Therapeutics Incorporated $CORT - Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) Corcept Therapeutics fell 0.1% today despite receiving a positive Committee for Medicinal Products for Human Use (CHMP) opinion recommending European Union marketing authorization for its drug Lifyorli® (relacorilant). The minimal decline suggests the market had largely priced in this regulatory milestone or viewed it as expected progress rather than a surprise catalyst. 18-SEP-2026 08:11 AM ET